证券代码：301333 证券简称：诺思格 公告编号：2023-024 诺思格（北京）医药科技股份有限公司 关于召开 2023 年第一次临时股东大会通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 根据诺思格（北京）医药科技股份有限公司（以下简称"公司"）第四届董 事会第十二次会议决议，公司董事会定于2023年08月31日（星期四）以现场表决 和网络投票相结合的方式召开公司2023年第一次临时股东大会，现将本次股东大 会的有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2023年第一次临时股东大会。 2、股东大会的召集人：公司董事会。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的有关规定。 4、会议召开的日期、时间： （1）现场会议：2023年08月31日（星期四）14:30 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为 2023年08月31日09:15-09:25，09:30-11:30 和13:00-15:00；通过深圳证券交易 所互联网投票系统 ...

本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、 独立董事辞职的基本情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"）董事会于近日 收到独立董事韩慧女士的书面辞职报告，韩慧女士因个人工作安排原因申请辞 去公司独立董事职务，同时一并辞去公司董事会提名委员会主任委员和战略委 员会以及薪酬与考核委员会委员。辞职后， 韩慧女士将不再担任公司任何职务。 证券代码：301333 证券简称：诺思格 公告编号：2023-023 诺思格（北京）医药科技股份有限公司 关于独立董事辞职暨选举独立董事候选人的公告 韩慧女士原定任期为 2021 年 12 月 27 日起至公司第四届董事会届满之日 止。因韩慧女士辞职，根据《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《上市公司独立董事规则》等法律法规、规范性文 件及《诺思格（北京）医药科技股份有限公司章程》（以下简称"《公司章程》"） 的规定，韩慧女士的辞职报告将在公司股东大会选举产生新任独立董事后方能 生效。韩慧女士在任职公司独立董事期间，勤勉尽责、独立公正，为公司的规 范运作和健康发展发挥 ...

诺思格（北京）医药科技股份有限公司 2023年限制性股票激励计划实施考核管理办法 诺思格（北京）医药科技股份有限公司（以下简称"公司"）为推进公司稳健 发展，进一步建立健全公司长效激励机制，吸引和留住优秀人才，充分调动公司高 级管理人员、中层管理人员、核心技术/业务人员积极性，有效将股东利益、公司 利益和核心团队个人利益结合在一起，增强公司整体凝聚力，使各方共同关注公司 的长远发展，确保公司发展战略和经营目标的实现，公司拟实施2023年限制性股票 激励计划（以下简称"股权激励计划"或"限制性股票激励计划"）。 为保证股权激励计划的顺利实施，现根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司股权激励管理办法》《深圳证券交易所创业板股票上市规则 （2023年修订）》《深圳证券交易所创业板上市公司自律监管指南第1号——业务 办理（2023年2月修订）》等有关法律法规、规范性文件和《公司章程》《诺思格（ 北京）医药科技股份有限公司2023年限制性股票激励计划（草案）》的有关规定， 并结合公司的实际情况，特制定公司《2023年限制性股票激励计划实施考核管理办 法》（以下简称"本办法"）。 一、考核目的 ...

证券代码：301333 证券简称：诺思格 公告编号：2023-019 （一）审议通过《关于<2023年限制性股票激励计划（草案）>及其摘要 的议案》 表决情况：3 票同意；0 票弃权；0 票反对。 经审议，监事会认为：《2023年限制性股票激励计划（草案）》及其摘要 的内容符合《公司法》《证券法》《上市公司股权激励管理办法》等相关法律、 法规和规范性文件的规定。本次激励计划的实施将有利于公司的持续发展， 不存在损害公司及全体股东利益的情形。 具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）披露的《2023 诺思格（北京）医药科技股份有限公司 第三届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"）第三届监事 会第九次会议于2023年08月09日在公司会议室以现场结合通讯方式召开。会 议通知已于2023年08月04日以电子邮件、专人送达等方式送达全体监事。本 次会议应出席监事3人，实际出席监事3人。会议由监事会主席关虹主持。会 议召开符合有关法 ...

诺思格（北京）医药科技股份有限公司董事会 诺思格（北京）医药科技股份有限公司 2023 年限制性股票激励计划的授予激励对象名单 2023年08月09日 注：1、上述任何一名激励对象通过全部有效的股权激励计划获授的本公司股票 均未超过公司总股本的1%。公司全部有效的激励计划所涉及的标的股票总数累计不 超过股权激励计划提交股东大会时公司股本总额的20%。 序号 激励对象 国籍 职务 获授限制性 股票数量 （万股） 占授予限制 性股票总数 的比例 占本激励计划 公告时公司股 本总额的比例 1 CHEN GANG （陈刚） 美国 副总经理 28.80 12.00% 0.30% 2 李继刚 中国 副总经理 10.65 4.44% 0.11% 3 王 涛 中国 副总经理 5.76 2.40% 0.06% 4 刘 萍 中国 副总经理 9.00 3.75% 0.09% 5 赵 倩 中国 财务总监 9.00 3.75% 0.09% 6 HE KUN (何崑) 美国 核心技术人员 11.52 4.80% 0.12% 其他中层管理人员、核心技术/业务人员 （245 人） 126.87 52.86% 1.32% 首次授予部分合计（2 ...

证券代码：301333 证券简称：诺思格 诺思格（北京）医药科技股份有限公司 投资者关系活动记录表 编号：2023-005 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他 （） 信达证券 金鹰基金 农银人寿 泰致资产 泰达宏利 中金基金 参与单位名称及 中加基金 人员姓名 时间 2023 年 05 月 10 日 地点 北京金融街丽思卡尔顿酒店 董事、副总经理：滕乐燕 上市公司接待人 证券事务代表：齐士坤 员姓名 1、国内医药研发、临床 CRO 外包宏观环境的变化情况？ 从去年三季度开始，我们观察到国内的临床试验需求端是 在一个逐步恢复的过程中，我们也逐渐的收到了更多的客户询 价和竞标的方面的需求，但同时在临床运营服务、数统服务以及 临床试验现场管理服务等多个业务版块的竞争也变得比较激 烈。 2、公司关于国际化的规划和部署情况？ 投资者关系活动 我们认为，海外临床药物研发的市场非常广阔，机遇也非常 多，这也是一家临床 CRO 公司想要发展壮大，必然要走的一个 主要内容介绍 方向。我们的国际化布局起步于美国子公司的设立，公司近几年 境外收 ...

Financial Performance - The company's operating revenue for 2022 was ¥637,520,243.17, representing a 4.78% increase from ¥608,425,821.40 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥113,592,222.90, a 14.47% increase compared to ¥99,237,035.17 in 2021[21]. - The net cash flow from operating activities for 2022 was ¥130,465,983.24, up 13.87% from ¥114,573,627.51 in 2021[21]. - The total assets at the end of 2022 amounted to ¥1,880,941,437.34, a significant increase of 177.64% from ¥677,471,603.55 at the end of 2021[21]. - The net assets attributable to shareholders at the end of 2022 were ¥1,587,985,580.78, reflecting a 275.83% increase from ¥422,531,037.54 at the end of 2021[21]. - The basic earnings per share for 2022 were ¥2.22, slightly up by 0.45% from ¥2.21 in 2021[21]. - The diluted earnings per share for 2022 were also ¥2.22, maintaining the same increase of 0.45% from ¥2.21 in 2021[21]. - The company reported a weighted average return on equity of 12.54% for 2022, down from 26.63% in 2021, indicating a decrease of 14.09%[21]. - The quarterly operating revenue for Q4 2022 was ¥169,334,232.02, showing a recovery from the previous quarters[23]. - The net profit attributable to shareholders in Q4 2022 was ¥29,747,636.27, indicating a positive trend in profitability towards the end of the year[23]. Dividend and Capital Reserves - The company plans to distribute a cash dividend of 2.50 RMB per 10 shares to all shareholders, based on a total of 60,000,000 shares[3]. - The company will also increase capital reserves by converting 6 shares for every 10 shares held by shareholders[3]. Risk Management and Compliance - The management discussed potential risks and countermeasures in the section on future development outlook[3]. - The report outlines the company's commitment to transparency and legal responsibility for the information provided[3]. - The company emphasizes the importance of risk awareness for investors regarding future plans and forecasts[3]. - The financial report has been confirmed as true, accurate, and complete by the company's responsible persons[3]. - The report is prepared in accordance with the relevant financial reporting standards and regulations[3]. Research and Development - The company has established a comprehensive R&D service system since its inception in 2008, focusing on clinical trial outsourcing services[34]. - The company aims to enhance its service capabilities in response to the rising internationalization of drug development and regulatory standards[33]. - The company emphasizes the importance of early identification of product viability and effective R&D strategies to meet market needs[32]. - The company has a strong focus on quality management and regulatory knowledge to assist clients in navigating complex industry environments[34]. - R&D expenses increased by 21.37% to ¥49,993,012.97, reflecting the company's commitment to innovation[60]. - The total R&D investment for 2022 was approximately ¥49.99 million, representing 7.84% of total revenue, an increase from 6.77% in 2021[62]. - The number of R&D personnel increased to 250 in 2022, up 16.28% from 215 in 2021, with a higher proportion of staff under 30 years old[62]. Market Expansion and Strategy - The company plans to undertake more international multi-center clinical research projects to compete directly with international CRO companies[87]. - The company is actively expanding its global footprint and innovating clinical trial technologies to meet international regulatory trends[51]. - The company focuses on providing comprehensive CRO services to global pharmaceutical enterprises, aiming to improve drug development success rates and reduce R&D risks[50]. - The company has ongoing projects focused on AI-assisted clinical trial design, aiming to enhance operational efficiency and attract early clients[60]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the biotech sector[119]. - Market expansion efforts include entering two new international markets, aiming for a 15% increase in market share by the end of 2023[118]. Corporate Governance - All board members attended the meeting to review the annual report[3]. - The board of directors consists of 9 members, including 3 independent directors, and held 8 meetings during the reporting period, adhering to legal and regulatory requirements[98]. - The supervisory board has 3 members, including 1 employee supervisor, and convened 6 meetings, all in compliance with legal and regulatory standards[99]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring no financial resources are misappropriated[104]. - The company has a governance structure that does not involve differential voting rights arrangements[112]. - The company is committed to maintaining the interests of minority shareholders and ensuring effective governance practices[137]. Employee Management - The company has established a complete and fair compensation management system to align employee interests with company performance, enhancing employee motivation[143]. - The company has implemented a training program to improve employee skills and efficiency, focusing on new employee orientation and ongoing education[144]. - The total number of employees at the end of the reporting period was 1,926, with 1,789 being technical personnel, representing approximately 92.9% of the workforce[142]. - The company has a total of 267 employees with a master's degree or higher, accounting for approximately 13.9% of the workforce[142]. Environmental and Social Responsibility - There were no reported environmental penalties or issues during the reporting period, indicating compliance with environmental regulations[158]. - The company aims to enhance its corporate culture, promoting values such as inclusivity, harmony, and professionalism[157]. - The company has not reported any significant actions regarding poverty alleviation or rural revitalization initiatives[163]. Future Outlook - Future outlook suggests a projected revenue growth of approximately 20% for 2023, driven by new product launches and market expansion strategies[116]. - The company is actively investing in R&D for new technologies, with a budget allocation of 5 million for the development of innovative pharmaceutical solutions[117]. - A new product line is expected to launch in Q3 2023, anticipated to contribute an additional 10% to overall revenue[120]. - The management team has undergone changes, with new appointments aimed at strengthening operational efficiency and strategic direction[121]. Shareholder Relations - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing[165]. - The company will not repurchase any shares that were issued prior to the public offering during the lock-up period[167]. - The company has fulfilled all commitments related to shareholding and lock-up periods as of the reporting date[165]. - The company reported a commitment to reduce shareholding after the lock-up period, with a maximum of 25% of shares held before the IPO to be sold within two years[174].

Financial Performance - The company's operating revenue for Q1 2023 was ¥160,932,583.88, a decrease of 5.47% compared to ¥170,242,153.31 in the same period last year[5] - Net profit attributable to shareholders increased by 7.63% to ¥28,792,801.97 from ¥26,751,469.21 year-on-year[5] - Basic earnings per share decreased by 18.64% to ¥0.48 from ¥0.59 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 160,932,583.88, a decrease of 5.7% compared to CNY 170,242,153.31 in Q1 2022[24] - Net profit for Q1 2023 reached CNY 28,678,469.89, an increase of 5.0% from CNY 27,307,384.49 in Q1 2022[26] - The total comprehensive income for the first quarter of 2023 was CNY 28,776,416.25, compared to CNY 27,327,655.65 in the same period last year, representing an increase of approximately 5.3%[27] Cash Flow and Investments - The net cash flow from operating activities surged by 324.03% to ¥17,791,127.98, compared to ¥4,195,764.85 in the previous year[14] - The company reported a cash inflow of CNY 153,077,038.71 from sales of goods and services, an increase from CNY 136,263,341.28 in the previous year, reflecting an increase of about 12.3%[29] - The total cash outflow from operating activities was CNY 141,395,795.77, compared to CNY 132,650,901.64 in the previous year, representing an increase of approximately 6.0%[30] - The net cash flow from investment activities was negative CNY 217,277,058.98, compared to negative CNY 17,572,346.41 in the same period last year, indicating a worsening of approximately 1,136.5%[30] - Cash inflow from investment activities totaled CNY 960,758,579.90, a substantial rise from CNY 183,873,392.38 in the previous year, reflecting an increase of about 421.5%[30] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,922,065,259.29, reflecting a significant increase of 187.20% from ¥669,236,394.13 at the end of the previous year[5] - Total liabilities increased to CNY 299,243,667.60 in Q1 2023, compared to CNY 286,982,213.23 in Q1 2022[23] - The company's total assets as of Q1 2023 amounted to CNY 1,922,065,259.29, up from CNY 1,880,941,437.34 in the previous year[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 3,657, with ACE UNION HOLDING holding 28.68% of the shares[15] - The first quarter report highlighted significant investments from major shareholders, including the Macau Monetary Authority and Kuwait Investment Authority, each holding approximately 1.42% of shares[18] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest being the Macau Monetary Authority with 853,506 shares[18] - The company has established consistent action agreements among major shareholders to maintain alignment on significant corporate matters[18] Financial Management - The company reported a significant increase in financial income, with a rise of 593.41% in financial expenses due to increased exchange gains and interest income[12] - Other income increased by 470.83% to ¥3,874,649.00, primarily due to government subsidies related to revenue[12] - The company is actively managing its financial assets, with a focus on optimizing liquidity and investment strategies[21] Future Outlook - Future outlook includes potential market expansion and new product development, although specific figures were not disclosed in the report[20]

诺思格（北京）医药科技股份有限公司 2023 年第一季度报告 证券代码：301333 证券简称：诺思格 公告编号：2023-008 诺思格（北京）医药科技股份有限公司 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 诺思格(北京)医药科技股份有限公司 2023 年第一季度报告 一、主要财务数据 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 口是 ☑否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | (%) | | 营业收入(元) | 160, 932, 583. 88 | 170, 242, 153. 31 ...